Rare Disease Diagnostics Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Rare Disease Diagnostics Market Between 2025 And 2029?

The rare disease diagnostics market size has demonstrated robust growth in recent years. It is anticipated to expand from $35.23 billion in 2024 to reach $38.14 billion by 2025, achieving a compound annual growth rate (CAGR) of 8.3%. This historical expansion can be linked to factors such as the increasing demand for cloud-based diagnostics, a greater emphasis on boosting efficiency, the rising prevalence of neurological diseases, an increase in immunological disorders, and higher healthcare expenditures.

The rare disease diagnostics market size is forecast to undergo substantial growth in the upcoming years, with projections indicating it will reach $56.08 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.1%. This expansion during the forecast period is propelled by factors such as the increasing prevalence of rare diseases, enhanced government initiatives, a rise in the number of hospitals and diagnostic laboratories, the growing incidence of hematology diseases, and an improving healthcare infrastructure. Notable trends expected over this period encompass advancements in genetic testing technologies, the introduction of whole-genome sequencing and next-generation sequencing (NGS), significant investments, and strategic collaborations aimed at research initiatives.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

Which Major Market Drivers Are Shaping The Future Of The Rare Disease Diagnostics Market?

The growing occurrence of rare diseases is anticipated to boost the expansion of the rare disease diagnostics market moving forward. A rare disease is defined as a health condition with low prevalence, impacting only a small fraction of the population when contrasted with more common illnesses. These diagnostic tools for rare diseases facilitate enhanced disease management, enable the discovery of suitable treatments, and prevent redundant therapies that could lead to severe adverse effects, thus supporting effective treatment. For example, in November 2022, Health Match, a digital health firm based in Australia, reported approximately 150 different rare kidney ailments. These conditions are widespread globally, with an incidence rate of 60–80 incidences per 100,000 people in America and Europe. Consequently, the rising prevalence of rare diseases is fueling the development of the rare disease diagnostics market.

How Is The Rare Disease Diagnostics Market Classified Into Different Segments?

The rare disease diagnosticsmarket covered in this report is segmented –

1) By Test Type: Genetic Test; General Lab Test; Imaging Test

2) By Technology: Capillary Sequencing; Whole Genome Sequencing; Whole Exome Sequencing; Microarrays

3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample; Buccal Swab Sample; Blood; Saliva

4) By Disease Type: Gastroenterology Disease; Endocrine And Metabolism Disorders Disease; Hematology And Oncology Disease; Dermatology Disease; Cardiovascular Disorders; Neurology Disease

5) By End User: Hospital Laboratories; Diagnostics Laboratories; Genetic Testing Laboratories; Cancer Research Laboratories

Subsegments:

1) By Genetic Test: Whole Genome Sequencing; Targeted Gene Panels; Exome Sequencing; Carrier Testing

2) By General Lab Test: Blood Tests; Biochemical Assays; Urine Tests; Cytogenetic Tests

3) By Imaging Test: MRI (Magnetic Resonance Imaging); CT (Computed Tomography) Scans; Ultrasound; X-Rays

How Are Emerging Market Trends Shaping The Rare Disease Diagnostics Industry Landscape?

Technological progress stands out as a significant and growing trend within the rare disease diagnostics market. Leading companies active in the rare disease diagnostics market are embracing novel technologies to maintain their competitive standing. An example of this is Centogene GmbH, a Germany-based rare disease company, which introduced CentoGenome in April 2023. This solution offers whole genome sequencing specifically for diagnosing rare and neurodegenerative conditions. CentoGenome functions as an improved next-generation sequencing (NGS)-based assay, providing whole genome sequencing (WGS) tests for both rare and neurodegenerative disorders. It is designed to identify nearly all relevant disease-causing variants through a single test. Furthermore, it demonstrates optimal sensitivity for identifying Copy Number Variations (CNVs) associated with Spinal Muscular Atrophy (SMA), alongside complex disease-causing variations related to Gaucher Disease (GD) and susceptibility to GBA1-related Parkinson’s Disease (PD). By incorporating PCR (polymerase chain reaction)-free technology in challenging genomic regions, CentoGenome is poised to significantly reduce bias and deliver superior sequencing data, thus enabling a more profound comprehension of coding, regulatory, and intronic areas.

Who Are The Top Performing Companies In The Rare Disease Diagnostics Market In Recent Years?

Major companies operating in the rare disease diagnostics market include Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Astellas Pharma Inc., Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, BioMarin Pharmaceutical Inc., OPKO Health Inc., Sarepta Therapeutics Inc., Natera Inc., Invitae Corporation, Ultragenyx Pharmaceutical Inc., Travere Therapeutics Inc., BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., Agios Pharmaceuticals Inc., Orphazyme A/S, RareCyte Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

Which Regional Markets Are Contributing Most To The Rare Disease Diagnostics Industry Expansion?

North America was the largest region in the rare disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Rare Disease Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2025, By The Business Research Company

Rare Diseases Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Rare Sugar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-sugar-global-market-report

Rare Kidney Diseases Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795